MedTrace Logo

Combination of Regorafenib and Nivolumab in Unresectable Hepatocellular Carcinoma

NCT04310709 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2022-12-06

No results posted yet for this study

Summary

Regorafenib and nivolumab are proven effective agents for the management of unresectable hepatocellular carcinoma patients. As preclinical studies have suggested potential synergism between antiangiogenic agents and immune checkpoint inhibitors, regorafenib and nivolumab may have synergism in terms of efficacy. Herein, this study investigates the combination of regorafenib and nivolumab as first-line therapy in patients with unresectable hepatocellular carcinoma.

Conditions

  • Carcinoma, Hepatocellular
  • Hepatoma

Interventions

DRUG

Regorafenib/Nivolumab

Combination of regorafenib and nivolumab

Sponsors & Collaborators

  • Samsung Medical Center

    collaborator OTHER

  • Bundang CHA Hospital

    collaborator OTHER

  • Asan Medical Center

    lead OTHER

Principal Investigators

  • Changhoon Yoo, MD, PhD · Asan Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-16
Primary Completion
2022-05-30
Completion
2022-11-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04310709 on ClinicalTrials.gov